Oral Bowel Disease Pill Beats Placebo, Clearing Path to Phase 3
GILD sits 38% above its 52-week low of $114.02.
Summary
Gilead's once-daily oral emvistegrast hit its main goal in a mid-stage ulcerative colitis trial: 66% of patients on the 200 mg dose improved versus 37% on placebo, and 31% reached clinical remission against 8% on placebo. The drug blocks the α4β7 integrin pathway, a validated IBD target, and side-effect rates matched placebo with no serious events tied to the study drug. BMO called it an incremental positive that makes emvistegrast a credible oral option in inflammatory bowel disease. The payoff is still years out — Gilead only plans to start a late-stage monotherapy study in 2027 — so this is pipeline validation rather than near-term revenue. It adds a second positive readout to a run that already includes the August Trodelvy EU approval and the Bixlenvo FDA approval, supporting the case that the $11.5B IPR&D spend is producing assets.
At the time of this announcement, GILD was trading at $156.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.7B. The 52-week trading range was $114.02 to $160.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.